Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

The prevalence of overweight and obesity has reached pandemic proportions, affecting more than 1 billion people worldwide; it ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School ...

OpenAI CEO Sam Altman said that he tried semaglutide "before it was cool," and his busy life has made it harder to focus on his health.

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with ...

Scientists say they’ve come up with a way for the body to produce its own store of glucagon-like peptide-1 (GLP-1). GLP-1 is ...

Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...